OTC drug review
Executive Summary
Is targeted for completion in about two years, FDA Advisor to the Commissioner Mary Pendergast told the Food and Drug Law Institute Dec. 10. "We agreed with the staff of the over-the- counter drug division that 19 years was long enough for the OTC review and we gave that office additional staffing and stature within the FDA," she remarked. "We set our sights on completing the review in a little more than two years not the seven or eight they thought it might take". . . .